A nursing researcher at Louisiana State University Health Sciences Center School of Nursing in New Orleans has found that many factors can impact the quality of life in people with pulmonary hypertension (PH), including mood, anxiety, stress, walking, and the availability of social support. PH is a chronic disease…
News
An international collaboration of researchers from the United States and China reported that adiponectin (APN), a protein that regulates glucose levels and fatty acid breakdown in the body, may be a naturally-occurring anti-fibrotic agent for systemic sclerosis (SSc). They presented their study at the 2014 American College of Rheumatology Meeting…
Findings from a study entitled “Right ventricular adaptation to pulmonary pressure load in patients with chronic thromboembolic pulmonary hypertension before and after successful pulmonary endarterectomy — a cardiovascular magnetic resonance study,” were recently published in the Journal of Cardiovascular Magnetic Resonance. Chronic thrombolic pulmonary hypertension (CTEPH)…
On Dec 10, 2014 iBio, Inc. revealed progress in developing IBIO-CFB03, a treatment for idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and other fibrotic diseases at its Annual Meeting. Unlike other proteins, which are produced by animals or cells in a dish, IBIO-CFB03 will be grown in plants. IPF is a…
GlaxoSmithKline (GSK) recently announced it has applied for a European Medicines Agency (EMA) variation to the Marketing Authorization for ambrisentan (Volibris®), in order to expand the currently approved indication to include its use as a first-line combination therapy with tadalafil for pulmonary arterial hypertension (PAH). Ambrisentan is classified as a…
Silence Therapeutics recently developed a genetic toolkit to support the company’s research into to several diseases, including pulmonary arterial hypertension (PAH). Specifically, Silence will utilize its new genetic toolkit to modulate gene expression and deliver unique systems to a variety of organs and cell types in pre-clinical in vivo animal…
The US Food and Drug Administration has granted San Diego-based regenerative-medicine company Cytori Therapeutics, Inc. conditional approval for an Investigational Device Exemption or IDE for a central study dubbed, STAR. The investigation will evaluate Cytori Cell Therapy‘s efficacy as a new solution for impaired hand function in patients with…
The right ventricle is extremely critical to the progression of pulmonary hypertension due to its position immediately before the pulmonary artery. It was previously shown the volume of the right ventricle can predict changes in clinically stable…
Although right heart catheterization is an invasive procedure, it can detect changes in right ventricular volume that predict clinical worsening of pulmonary arterial hypertension. A study from the Department of Pulmonary Diseases at VU University Medical Center in Amsterdam, “Signs of Right Ventricular Deterioration in…
A research group from New York Medical College has found a gene that may control pulmonary hypertension severity, as well as the less severe form that occurs in women versus men. The article appeared November 21, 2014, in the journal Molecular Medicine. entitled, “Deletion of STAT5a/b in…
Courtesy of EchoSense Two clinical trials from EchoSense Ltd. are directed toward using lung Doppler signals (LDS) to predict the risk for pulmonary hypertension in patients with systemic sclerosis (SSc). The trials will evaluate the feasibility of identifying pulmonary vessels characteristics using LDS and EchoSense’s processing…
Actelion Pharmaceuticals Ltd., has just announced its has sent the European Medicines Agency (EMA) an application for the centralized Marketing Authorization of selexipag (Uptravi®), indicated for the treatment of pulmonary arterial hypertension (PAH). While the drug’s MAA is pending validation, the company is working…
